However, after treatment with FAP inhibitor Talabostat, T2DM-induced HFpEF mice showed weight loss and a nearly normal decrease in FBG levels, with significant differences in IPGTT and ITT compared with T2DM-induced HFpEF mice (Figure 7b, c, d and e). Here, FAP is linked to type 2 diabetes mellitus.